Paper Details

  1. Home
  2. Paper Details

A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection.

Author: FuX X, HaoL J, HuangfuY S, SuC X, TianG S, XuD Z, YaoG B

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study found that consensus interferon was safe and effective at concentrations of 9 and 15 microg in Chinese patients with chronic hepatitis C. 15 microg CIFN may be more effective than 3 MU IFN-alpha-2a without increased toxicity.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Alpha-interferons are the accepted therapy for patients infected with chronic hepatitis C virus (HCV) in China. However, consensus interferon (CIFN) for HCV treatment is effective in patients with chronic hepatitis C from Western countries. METHODS: This randomized, controlled trial was...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1046/j.1440-1746.2000.02307.x

データ提供：米国国立医学図書館（NLM）

Interferon Alfacon-1: A Potential Oasis in the Desert of Hepatitis C

Hepatitis C, a disease that can wreak havoc on the liver, is like a relentless sandstorm, threatening the health and well-being of those infected. This multicenter, randomized controlled trial delves into the effectiveness of interferon alfacon-1, a potential oasis in the desert of hepatitis C treatment. The study compares the safety and efficacy of interferon alfacon-1 to alpha-2a-interferon, a commonly used treatment, in Chinese patients with chronic hepatitis C virus infection. The researchers used a rigorous approach, akin to carefully navigating through a treacherous desert landscape, ensuring the study's findings are reliable and applicable to the real-world setting.

A Beacon of Hope in the Sandstorm

The study's findings are like discovering a hidden well of clear water in a parched desert. Interferon alfacon-1 emerged as a promising treatment option, particularly at a higher dose, showing greater efficacy in achieving sustained response compared to alpha-2a-interferon. The results provide a valuable insight into the potential of interferon alfacon-1 as a treatment strategy for hepatitis C, offering hope for those battling this debilitating disease.

Navigating the Desert of Hepatitis C Treatment

The findings of this study provide a roadmap for navigating the desert of hepatitis C treatment. It suggests that interferon alfacon-1 might be a valuable weapon in the fight against this disease. However, like any journey through the desert, individualized care and careful monitoring are essential. Patients should work closely with their healthcare providers to determine the most appropriate treatment strategy based on their individual circumstances and risk factors.

Dr. Camel's Conclusion

The desert of hepatitis C is vast and unforgiving, but this study offers a glimmer of hope. Interferon alfacon-1, a potential oasis in this parched landscape, demonstrates significant promise in treating this debilitating disease. However, we must continue our journey, seeking more effective treatment strategies and personalized care to ensure every traveler finds their way through this challenging desert.

Date :
  1. Date Completed 2001-05-31
  2. Date Revised 2019-08-31
Further Info :

Pubmed ID

11106097

DOI: Digital Object Identifier

10.1046/j.1440-1746.2000.02307.x

Related Literature

Article Analysis
・Effective treatment of hepatitis c
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.